Anbio Biotechnology director files initial Form 3

Anbio Biotechnology director David H. Hsu filed an initial ownership report on Form 3.

Accepted by SEC EDGAR 06/12/2026 - 10:45 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Anbio Biotechnology director David H. Hsu filed an initial ownership report on Form 3. The filing identifies him as a director and not a ten percent owner, and shows no reported transactions or specific share holdings in this data excerpt.

Key Terms

Form 3, reporting person, ten percent owner

3 terms

Form 3 regulatory

"Anbio Biotechnology director David H. Hsu filed an initial ownership report on Form 3."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [{ "name": "HSU DAVID H" }]"

ten percent owner regulatory

""is_ten_percent_owner": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Anbio Biotechnology (NNNN) Form 3 filing show for David H. Hsu?

The Form 3 shows that David H. Hsu is a director of Anbio Biotechnology and not a ten percent owner. The summarized data reports no insider transactions or specific holdings in this excerpt.

Does the Anbio Biotechnology (NNNN) Form 3 report any insider share purchases or sales?

No insider share purchases or sales are reported in this Form 3 summary. The transaction counts for buys, sells, exercises, gifts, and tax withholdings are all zero in the provided data.

Is David H. Hsu a ten percent owner of Anbio Biotechnology (NNNN) according to the Form 3?

According to the Form 3 data, David H. Hsu is not a ten percent owner of Anbio Biotechnology. He is categorized only as a director, with the ten percent owner flag marked as zero.

Does the Anbio Biotechnology (NNNN) Form 3 include any derivative security positions?

The Form 3 summary shows no derivative security positions for David H. Hsu. The derivativeSummary is empty and derivativeTransactionCount is zero, indicating no options or similar instruments reported here.

What is the overall net buy or sell direction in this Anbio Biotechnology (NNNN) Form 3?

The Form 3 shows a neutral net buy or sell direction for David H. Hsu. NetBuySellShares is zero and netBuySellDirection is labeled as neutral, reflecting no reported trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

HSU DAVID H

(Last) (First) (Middle)

FRIEDRICH-EBERT-ANLAGE 35-37

(Street)

FRANKFURT AM MAIN 60327

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Anbio Biotechnology [ NNNN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ David Hsu	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)